{"entity":{"id":"nct06568094","kind":"trial","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06568094 as recruiting, last updated 2026-09-17. Enrolment is 100 planned participants, an estimate. Interventions: HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets, Docetaxel Injection, HRS-1167 tablets, SHR2554 tablets, HRS-6208 capsules, HRS-2189 Tablets. Primary measures include Recommended phase II dose (Phase Ib); Incidence and severity of adverse events (AE) (Phase Ib). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06568094","url":"https://clinicaltrials.gov/study/NCT06568094"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["prednisone","docetaxel","darolutamide","hrs-1167"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06568094","phase":"1/2","setting":"An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT06568094","source":"https://clinicaltrials.gov/study/NCT06568094","fetchedAt":"2026-10-07T16:54:48.431Z","studySha256":"98784114826fdc00efbc974e54c308045f272ea0d438dc5c84f60c99cd8cbc68","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-17","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["China"]}],"started":"2024-09-25","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06568094/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}